BRPI0814957B8 - composto, agente farmacêutico, e, uso do composto - Google Patents

composto, agente farmacêutico, e, uso do composto

Info

Publication number
BRPI0814957B8
BRPI0814957B8 BRPI0814957A BRPI0814957A BRPI0814957B8 BR PI0814957 B8 BRPI0814957 B8 BR PI0814957B8 BR PI0814957 A BRPI0814957 A BR PI0814957A BR PI0814957 A BRPI0814957 A BR PI0814957A BR PI0814957 B8 BRPI0814957 B8 BR PI0814957B8
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical agent
prodrug
salt
formula
Prior art date
Application number
BRPI0814957A
Other languages
English (en)
Portuguese (pt)
Inventor
Hasuoka Atsushi
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of BRPI0814957A2 publication Critical patent/BRPI0814957A2/pt
Publication of BRPI0814957B1 publication Critical patent/BRPI0814957B1/pt
Publication of BRPI0814957B8 publication Critical patent/BRPI0814957B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/54—Spiro-condensed

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0814957A 2007-08-07 2008-08-06 composto, agente farmacêutico, e, uso do composto BRPI0814957B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007205966 2007-08-07
JP2007299658 2007-11-19
PCT/JP2008/064500 WO2009020234A2 (en) 2007-08-07 2008-08-06 Pyrrolidin-2 -one derivatives as androgen receptor modulator

Publications (3)

Publication Number Publication Date
BRPI0814957A2 BRPI0814957A2 (pt) 2015-02-03
BRPI0814957B1 BRPI0814957B1 (pt) 2019-12-03
BRPI0814957B8 true BRPI0814957B8 (pt) 2021-05-25

Family

ID=40329363

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0814957A BRPI0814957B8 (pt) 2007-08-07 2008-08-06 composto, agente farmacêutico, e, uso do composto

Country Status (34)

Country Link
US (2) US8420694B2 (enExample)
EP (1) EP2176220B1 (enExample)
JP (1) JP5292390B2 (enExample)
KR (1) KR20100049644A (enExample)
CN (1) CN101821235B (enExample)
AR (1) AR067823A1 (enExample)
AU (1) AU2008284662B2 (enExample)
BR (1) BRPI0814957B8 (enExample)
CA (1) CA2695852C (enExample)
CL (1) CL2008002313A1 (enExample)
CO (1) CO6160326A2 (enExample)
CR (1) CR11266A (enExample)
CY (1) CY1114067T1 (enExample)
DK (1) DK2176220T3 (enExample)
DO (1) DOP2010000053A (enExample)
EA (1) EA017429B1 (enExample)
ES (1) ES2406685T3 (enExample)
GE (1) GEP20125571B (enExample)
HR (1) HRP20130374T1 (enExample)
JO (1) JO2864B1 (enExample)
MA (1) MA31639B1 (enExample)
ME (1) ME01579B (enExample)
MX (1) MX2010001484A (enExample)
MY (1) MY159910A (enExample)
NZ (1) NZ583624A (enExample)
PE (1) PE20090899A1 (enExample)
PL (1) PL2176220T3 (enExample)
PT (1) PT2176220E (enExample)
RS (1) RS52812B (enExample)
SI (1) SI2176220T1 (enExample)
TN (1) TN2010000062A1 (enExample)
TW (1) TWI418543B (enExample)
WO (1) WO2009020234A2 (enExample)
ZA (1) ZA201001289B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY159910A (en) * 2007-08-07 2017-02-15 Takeda Pharmaceuticals Co Pyrrolidin-2-one derivatives as androgen receptor modulator
BRPI0907844B8 (pt) * 2008-02-22 2021-05-25 Radius Health Inc compostos e método para modular um receptor de andrógeno, processos de preparação e composição farmacêutica dos mesmos e seus usos
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
US20090270361A1 (en) * 2008-03-26 2009-10-29 Takeda Pharmaceutical Company Limited Substituted pyrazole derivatives and use thereof
JP5964756B2 (ja) 2010-02-04 2016-08-03 ラジウス ヘルス，インコーポレイテッド 選択的アンドロゲン受容体モジュレーター
PL2568806T3 (pl) 2010-05-12 2017-03-31 Radius Health, Inc. Schematy lecznicze
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
AU2011312490B2 (en) * 2010-09-28 2015-06-25 Radius Pharmaceuticals, Inc. Selective androgen receptor modulators
US20150057452A1 (en) * 2012-04-04 2015-02-26 Catylix, Inc. Selective androgen receptor modulators
EP3158995B1 (en) 2012-08-09 2018-05-23 Dynamis Therapeutics, Inc. Meglumine for reducing high triglyceride levels
WO2014044357A1 (de) 2012-09-21 2014-03-27 Merck Patent Gmbh Verbindungen mit einer c-c-dreifachbindung und deren verwendung in flüssigkristallmischungen
ES2939940T3 (es) 2014-03-28 2023-04-28 Univ Duke Tratamiento del cáncer de mama utilizando moduladores selectivos de los receptores de estrógenos
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
KR101597327B1 (ko) 2014-04-24 2016-02-24 동아에스티 주식회사 옥사졸리딘계 화합물 및 이를 포함하는 선택적 안드로겐 수용체 효능제
CN103951688B (zh) * 2014-05-06 2016-04-20 成都安斯利生物医药有限公司 一种制备3,5-二氟-4-甲基苯硼酸的方法
WO2017223115A1 (en) 2016-06-22 2017-12-28 Radius Health, Inc. Ar+ breast cancer treatment methods
EP3565542B1 (en) 2017-01-05 2024-04-10 Radius Pharmaceuticals, Inc. Polymorphic forms of rad1901-2hcl
SG11202013177WA (en) 2018-07-04 2021-01-28 Radius Pharmaceuticals Inc Polymorphic forms of rad 1901-2hcl
WO2020144375A1 (en) 2019-01-11 2020-07-16 Grünenthal GmbH Substituted pyrrolidine amides iii
US12441745B2 (en) 2019-02-12 2025-10-14 Radius Pharmaceuticals, Inc. Processes and compounds
CN110204505B (zh) * 2019-05-31 2023-02-03 荆门医药工业技术研究院 (s)-3-苄氧羰基-4-异丙基-2,5-恶唑烷二酮的制备工艺
US20230012570A1 (en) * 2019-11-20 2023-01-19 Medshine Discovery Inc. Bicyclic compound used as selective androgen receptor modulator
CA3251059A1 (en) 2022-05-02 2023-11-09 The Board Of Trustees Of The Leland Stanford Junior University Compositions, systems and methods for modulating a target gene

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4141399A1 (de) 1991-12-16 1993-06-17 Bayer Ag 4-(substituierte)amino-3-arylpyrrolinon-derivate
WO2000017163A1 (en) * 1998-09-22 2000-03-30 Yamanouchi Pharmaceutical Co., Ltd. Cyanophenyl derivatives
US6258833B1 (en) 1999-12-23 2001-07-10 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US7026500B2 (en) 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
JP2002088073A (ja) * 2000-09-08 2002-03-27 Yamanouchi Pharmaceut Co Ltd 抗アンドロゲン剤
FR2817472B1 (fr) 2000-12-06 2003-01-03 Oreal Composition de teinture d'oxydation a base de 1-(4-aminophenyl)pyrrolidines substituees au moins en position 2 et 3 et procede de teinture de mise en oeuvre
PT1463497E (pt) 2001-12-06 2011-12-20 Gtx Inc Tratamento do desgaste muscular com moduladores selectivos do receptor de androgénios
JP4316232B2 (ja) 2001-12-28 2009-08-19 武田薬品工業株式会社 アンドロゲン受容体拮抗剤
CA2471754A1 (en) 2001-12-28 2003-07-17 Takeda Chemical Industries, Ltd. Androgen receptor antagonist
AU2003241583B2 (en) 2002-06-17 2009-05-21 University Of Tennessee Research Foundation N-bridged selective androgen receptor modulators and methods of use thereof
NZ538713A (en) 2002-08-12 2007-01-26 Takeda Chemical Industries Ltd Fused benzene derivative and use
GB0402492D0 (en) 2004-02-04 2004-03-10 Pfizer Ltd Pharmaceutically active compounds
US8519158B2 (en) 2004-03-12 2013-08-27 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
MXPA06013115A (es) * 2004-05-11 2007-02-28 Pfizer Prod Inc Derivados de benzonitrilo para tratar la fragilidad musculoesqueletica.
EP1756101A2 (en) 2004-05-17 2007-02-28 Acadia Pharmaceuticals Inc. Androgen receptor modulators and method of treating disease using the same
DK2289872T3 (en) 2004-06-07 2017-10-09 Univ Tennessee Res Found Medical use of a selective androgen receptor modulator
NZ555974A (en) 2005-01-10 2010-11-26 Acadia Pharm Inc Aminophenyl derivatives as selective androgen receptor modulators
TW200724139A (en) * 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators
DE602006003432D1 (de) 2005-05-13 2008-12-11 Lilly Co Eli Latoren des androgenrezeptors
WO2007015567A1 (ja) 2005-08-01 2007-02-08 Takeda Pharmaceutical Company Limited 環状アミン化合物
JPWO2007097289A1 (ja) 2006-02-20 2009-07-16 武田薬品工業株式会社 新規医薬
WO2008011072A2 (en) 2006-07-19 2008-01-24 Osurf (Ohio State University Research Foundation) Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof
RU2009106214A (ru) 2006-07-26 2010-09-10 Новартис АГ (CH) Ингибиторы ундекапренилпирофосфатсинтазы
CA2670976C (en) 2006-11-30 2015-01-27 Atsushi Hasuoka Cyclic amine compound
MY159910A (en) 2007-08-07 2017-02-15 Takeda Pharmaceuticals Co Pyrrolidin-2-one derivatives as androgen receptor modulator

Also Published As

Publication number Publication date
PL2176220T3 (pl) 2013-08-30
HRP20130374T1 (en) 2013-05-31
RS52812B (sr) 2013-10-31
TN2010000062A1 (en) 2011-09-26
BRPI0814957A2 (pt) 2015-02-03
TW200916439A (en) 2009-04-16
CA2695852C (en) 2017-01-03
EA201070246A1 (ru) 2010-08-30
DK2176220T3 (da) 2013-06-10
SI2176220T1 (sl) 2013-05-31
EP2176220B1 (en) 2013-03-27
MY159910A (en) 2017-02-15
ME01579B (me) 2014-09-20
US20110098336A1 (en) 2011-04-28
US7834051B2 (en) 2010-11-16
CL2008002313A1 (es) 2009-05-15
ZA201001289B (en) 2011-04-28
AU2008284662A1 (en) 2009-02-12
MA31639B1 (fr) 2010-08-02
GEP20125571B (en) 2012-07-10
JO2864B1 (en) 2015-03-15
US8420694B2 (en) 2013-04-16
NZ583624A (en) 2012-06-29
CA2695852A1 (en) 2009-02-12
DOP2010000053A (es) 2010-07-15
MX2010001484A (es) 2010-03-04
EP2176220A2 (en) 2010-04-21
JP2010535704A (ja) 2010-11-25
JP5292390B2 (ja) 2013-09-18
WO2009020234A2 (en) 2009-02-12
KR20100049644A (ko) 2010-05-12
US20090042967A1 (en) 2009-02-12
CO6160326A2 (es) 2010-05-20
CY1114067T1 (el) 2016-07-27
HK1143972A1 (en) 2011-01-21
CR11266A (es) 2010-03-22
PE20090899A1 (es) 2009-08-06
BRPI0814957B1 (pt) 2019-12-03
PT2176220E (pt) 2013-04-09
AU2008284662B2 (en) 2013-07-25
WO2009020234A3 (en) 2009-04-16
TWI418543B (zh) 2013-12-11
EA017429B1 (ru) 2012-12-28
ES2406685T3 (es) 2013-06-07
CN101821235A (zh) 2010-09-01
CN101821235B (zh) 2012-11-14
AR067823A1 (es) 2009-10-21

Similar Documents

Publication Publication Date Title
BRPI0719393B8 (pt) composição farmacêutica
BRPI0621386B8 (pt) composição farmacêutica para o uso externo
TW200744588A (en) Pharmaceutical composition for external use
BRPI0715579A2 (pt) "composto, composição farmacêutica e uso de um composto"
BR112016011755A2 (pt) derivado de ureia ou sal farmacologicamente aceitável do mesmo
EA200971081A1 (ru) Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7
TN2010000062A1 (en) Pyrrolidin -2-one derivatives as androgen receptor modulator
HRP20120323T1 (en) Diarylhydantoin compounds
BR112012027373A2 (pt) composição pesticida e seu uso
UY31145A1 (es) Derivado de 17b+ciano-18a-homo-19-nor-androst-4-eno, su uso y medicamento que lo contiene
EA201000089A1 (ru) Применение гомо- и сополимеров для стабилизации составов активных ингредиентов
BR112013004368A2 (pt) compostos tendo a fórmula geral (i) e composição farmacêutica
MY153915A (en) Organic compounds
BRPI0511504A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, e, agente preventivo ou terapêutico para uma doença resultante de beta-amilóides
ES2531009T3 (es) Análogos sustituidos de dicetopiperazina para su uso como agentes para la administración de fármacos
MX2012007098A (es) Derivados fenolicos y su uso farmaceutico o cosmetico.
UY31736A (es) Derivados sustituidos de pirazol y su uso
GEP20125404B (en) Tricyclic compounds and their use as glucocorticoid receptor modulators
SG163585A1 (en) Melanocortin receptor ligands
MY151295A (en) Pyrimidyl indoline compound
WO2010054286A3 (en) Substituted hydroxyphenylamine compounds
MX374628B (es) Formulacion que comprende un agente hipolipidemico.
MX2009008028A (es) Agentes antiparasitarios.
CL2008001990A1 (es) Compuestos derivados de amino-quinazolinas sustituidas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de alzheimer.
CO6251376A2 (es) Triazolilpiridina cetonas herbicidas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/12/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/12/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/08/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B15V Prolongation of time limit allowed
B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2786 DE 28-05-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.